Kazia Therapeutics Annual Report 2021

2021 AT A GLANCE CHAIRMAN’S LETTER CEO’S REPORT KEY MILESTONES PIPELINE REVIEW PARTNER FOR SUCCESS WORK WITH THE BEST #2 IN THE KAZIA STORY FINANCIAL REPORTS Kazia Therapeutics Limited Annual Report 2021 27 Short-term benefits Post- employment benefits Share- based payments Movements in accrued leave Non- monetary Salary & fees Cash Bonus Cash Super- annuation Options Equity- settled Total 2021 $ $ $ $ $ $ Non-Executive Directors: I Ross* 147,436 20,000 - - 119,067 286,503 B Carmine 82,500 22,500 - 9,975 119,067 234,042 S Coffey 82,500 22,500 - 9,975 119,067 234,042 Executive Directors: J Garner 503,000 240,000 90,400 70,585 228,651 1,132,636 Other Key Management Personnel: G Heaton 204,000 25,000 (241) 21,755 15,069 265,583 K Hill 108,525 26,400 - - 15,677 150,602 1,127,961 356,400 90,159 112,290 616,598 2,303,408 * Salary paid in UK pounds, but disclosed in Australian dollars using a conversion rate of 0.5562